- Healthy male and female subjects of non-childbearing potential between the ages of 21
- No evidence of active or latent TB.
- An informed consent document signed and dated by the subject.
- Evidence, including abnormal clinical laboratory parameters, eg, liver enzyme
elevations, or a history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
allergic disease (including drug allergies, but excluding untreated, asymptomatic,
seasonal allergies at time of dosing).
- Any condition possibly affecting drug absorption (eg, gastrectomy) or any active GI
disease (including any relevant surgery).
- Any current and clinically significant skin lesions as described in Common Terminology
Criteria for Adverse Events for Dermatology (CTCAE) Version 3. A clinically
significant skin lesion is defined as Grade 1 (mild) for rash and pruritus, and Grade
2 (moderate) or above for all other lesions (see Short Name description in CTCAE for
specific description of lesion).
- Use of prescription or nonprescription drugs, vitamins and dietary supplements within
7 days or 5 half-lives (whichever is longer) prior to the first dose of study
- Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or
investigational product administration or may interfere with the interpretation of
study results and, in the judgment of the investigator, would make the subject
inappropriate for entry into this study.